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ABSTRACT
Background: Major depressive disorder is a condition associated with dysregulated cytokine levels; among these, 
IL6. Furthermore, genetic variations within cytokine genes have been proposed to predict antidepressant treatment 
outcome.
Objectives: This study aims to evaluate the role of IL6-174G > C and IL6R D358A A > C functional polymorphisms in 
antidepressant treatment phenotypes, specifically remission, relapse, and treatment resistant depression (TRD).
Methods: The referred polymorphisms were genotyped in 80 MDD patients followed at Hospital Magalh~aes 
Lemos, Portugal, within a period of 27 months.
Results: It was found that patients carrying IL6-174 GC genotype present a protection towards the development of 
TRD (OR ¼ 0.242; 95% CI ¼ 0.068–0.869; p ¼ .038), when compared with GG genotype. Additionally, carriers of IL6-174 CC 
genotype remit earlier than patients with IL6-174 GG/GC genotypes, with a median time to remission of 6 weeks for 
CC carriers and 15 weeks for GG or GC carriers (p ¼ .030, Log-rank test). No association was found between IL6R 
D358A genetic polymorphism and any of the treatment phenotypes evaluated.
Conclusions: The IL6-174G > C polymorphism influences antidepressant treatment outcome in this sub-set of MDD 
patients, providing a putative mechanistic link for the dysregulated IL-6 levels described in the literature in 
patients with TRD.
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Background
Major Depressive Disorder (MDD) represents, nowadays, one
of the major causes of disability. Even though effective anti-
depressant treatments are available in the clinical setting,
approximately one third of all patients fail to respond to
antidepressant drugs (AD), contributing to the global burden
of this condition (1). Despite its prevalence, the exact frame-
work that contributes to depression and to AD response is
far of being totally understood. Emerging studies have been
pointing out the inflammatory response as a potential con-
tributor to the pathophysiology of depression. Among these,
the increased production of pro-inflammatory cytokines,
such as interleukin 6 (IL-6), is one of the most reliable bio-
markers (2). Patients with MDD have been shown to have
elevated serum and plasma IL-6 levels (3). The same evi-
dence is also found among patients with Treatment
Resistant Depression (TRD) (4–7). Modulation of the
inflammatory response and cell-mediated immunity has
been suggested as one possible mechanism explaining anti-
depressant mechanism of action (8,9). Additionally, treat-
ment with selective serotonin reuptake inhibitors (SSRI) AD
reduced serum IL-6 levels in patients with MDD (10), and
ketamine, a fast-acting antidepressant, has proven to reduce
IL-6 levels in the rat prefrontal cortex and hippocampus
(11). IL6 gene is located in chromosome 7, and it’s organ-
ized into five exons and four introns, and its expression
might be modulated by polymorphisms, such as rs1800795
in the promoter region of IL6 (12). However, despite the
clear influence of IL-6 in the pathophysiology of depression,
and in antidepressant response, studies evaluating the
impact of IL6 genetic polymorphisms on treatment response
phenotypes are scarce and only address response, not
relapse or TRD phenotypes (13). Additionally, and despite
TRD is a clinical important issue, to the best of our
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knowledge, no studies have associated the effect of IL6 and
IL6R genetic polymorphisms and TRD.
Aims
In this study, we aim to evaluate the role of IL6-174G> C
rs1800795 and IL6R D358A A>C rs8192284 functional
polymorphisms in antidepressant treatment response
phenotypes.
Materials and methods
Patients
For the analysis of the effect of IL6 and IL6R single nucleotide
polymorphism (SNPs) in AD treatment response phenotypes,
a cohort of 80 MDD patients was recruited at Hospital
Magalh~aes Lemos, Oporto, Portugal, and followed for 27
months (14,15). MDD diagnosis was accomplished with
Structured Clinical Interview for DSM-IV Axis I Disorders
(SCID-I) and the severity of the depressive symptoms with
Beck Inventory Depression (BDI). Pharmacological treatment
was chosen according to the Major Depressive Disorder treat-
ment algorithm of the Texas Medication Algorithm Project
(TMAP) (16). The first medicine was selected from the drugs
included in the first line of approach of the TMAP.
Pharmacotherapeutic effectiveness (administered after at
least 6 weeks and at adequate doses according to the TMAP
protocol) was determined as the change in the BDI score.
When patients present a BDI score less than 10 after 6 weeks
of at least one single adequate antidepressant treatment and
absence of criteria of MDD according to SCID-I were consid-
ered remitters. Antidepressant medication could be changed
for non-response or intolerably as per the TMAP protocol.
When the patient failed to reach a BDI score less than 10
and present criteria of MDD according to SCID-I, after at least
two adequate antidepressant treatments with different drugs
within the current episode, they were considered presenting
a ‘Treatment resistant depression’ (TRD) phenotype. Relapse
was defined as any depressive episode, upon remission, dur-
ing the follow-up time. When the patient displayed TRD or
relapsed they were considered as being part of a Bad
Prognosis phenotype. The evaluated AD treatment response
phenotypes were: TRD, relapse, time to remission, and time
to relapse. Clinical and sociodemographic characteristics of
the patients were described elsewhere (14). The study was
approved by the ethical committee of Hospital Magalh~aes
Lemos and written informed consent according to ‘The Code
of Ethics of the World Medical Association’ (Declaration of
Helsinki) was obtained from each individual after explanation
of the study.
DNA extraction and SNP analysis
Genomic DNA was extracted from the whole blood with a
commercial kit (E.Z.N.A. – Omega Bio-tek) according to the
manufacturer’s instructions, and stored at 20 C. The IL6-
174G>C (rs1800795) and IL6R D358A A> C (rs8192284)
polymorphisms analysis was carried out using Sequenom
MassARRAY technology (Sequenom, San Diego, CA).
Genotyping data was read blind to the clinical course of ill-
ness and, in the case of ambiguous genotypic data, experi-
ments were repeated for determining the genotype of every
individual.
Statistical analysis
Data preparation and analysis was carried out using the com-
puter software PAWS Statistics 18 (release 18.0.0). A 5% level
of significance was used in the Chi-square (v2) analysis to
compare the categorical variables. Odds ratio (OR) and 95%
confidence interval (CI) were calculated as a measure of asso-
ciation between genotypes and risk of developing a specific
phenotype. Kaplan–Meier survival curves were used to evalu-
ate the correlation between genotypes and time to remission
and relapse and were compared by log-rank statistical test.
The Hardy–Weinberg equilibrium of genotypic frequencies
was determined by Chi-square (v2).
Results
The genotype frequencies of IL6-174G> C (rs1800795) and
IL6R D358A A>C (rs8192284) polymorphisms among MDD
patients and its distribution among different treatment
response phenotypes are presented in Table 1. The distribu-
tion of IL6 rs1800795 and IL6R rs8192284 gene polymor-
phisms were consistent with the Hardy–Weinberg
equilibrium (p> .05, results not shown). Patients carrying
IL6-174GC genotype presented approximately a 75% a
reduced risk to develop TRD, when compared with the ones
carrying GG genotype (OR¼ 0.242; 95% CI¼ 0.068–0.869;
p¼ .038). No association between this polymorphism and
relapse was observed. Kaplan–Meier survival curves were
used to evaluate the correlation between genotypes and
time to remission and time to relapse and were compared
by Log-rank statistical test. It was observed that carriers of
the IL6-174CC genotype seem to remit earlier than patients
carrying the IL6-174 GG and GC genotypes, with a median
time to remission of 6 weeks for CC carriers and 15 weeks
for GG/GC carriers (Figure 1, p¼ .030, Log-rank test). No
association between this polymorphism and time relapse
was observed. Regarding IL6R D358A (rs8192284) polymorph-
ism, no statistically significant association was found
between genotype frequencies and antidepressant treatment
phenotypes, namely TRD and relapse, as well as time to
remission or relapse.
Discussion
Recent evidence suggests that MDD is a systemic condition,
where central and peripheral inflammatory changes seem to
have a main role in its pathophysiology. Among these, ele-
vated IL-6 plasma or serum levels are one of the most con-
sistent MDD biomarkers, and a top indicator of suicide risk
(17,18). Further research has indicated that genetic varia-
tions within cytokine genes may also predict the AD
treatment outcome (19). However, the deregulatory mech-
anism of IL-6 in MDD, and its normalization upon AD treat-
ment, is poorly understood. This way, we have determined
IL6-174G>C (rs1800795), and IL6R D358A A>C (rs8192284)
genotype and allele carrier frequencies in a cohort of
patients with MDD, treated according to the Texas
Medication Algorithm.
We observed that patients carrying IL6-174 GC genotype
presented a protection for the development of TRD, when
compared with GG genotype. According to the literature,
IL6-174G>C SNP (rs1800795) results in a functional alter-
ation, and healthy individuals, who harbour the
homozygous GG polymorphism, have been described to
have higher IL-6 concentrations than G/C or CC genotype
(20). We hypothesized that the presence of GG genotype
may turn out to be a risk factor of TRD, through its ability
of modulating IL-6 expression. Conversely, we observed that
carriers of CC genotype remit earlier, corroborating the
putative influence of this polymorphism in the AD treat-
ment response. This functional IL6 (rs1800795) polymorph-
ism is located in the promoter region of the IL6 gene and
has been previously associated with an increased risk of
IFN-induced depression (21). Interestingly, in patients under-
going antiviral treatment, subjects carrying CC genotype
Table 1. Overview of the association between genotypes or alleles under investigation and outcomes.
IL6-174 rs1800795 G/C IL6R rs2228145 A/C
No Yes No Yes
n % n % OR 95% CI p-value n % n % OR 95% CI p-value
Releapsed GG 14 31.1 6 37.5 1.0 Referent — AA 17 37.8 5 31.3 1.0 Referent —
GC 22 48.9 8 50.0 0.848 0.242–2.970 .797 AC 18 40.0 10 62.5 1.889 0.535–6.670 .320
CC 9 20.0 2 12.5 0.519 0.085–3.156 .676 CC 10 22.2 1 6.2 0.340 0.035–3.340 .637
C carrier 31 68.9 10 62.5 0.753 0.228–2.481 .640 C carrier 28 62.2 11 68.8 1.336 0.396–4.510 .640
Resistant (TRD) GG 20 32.8 11 57.9 1.0 Referent — AA 22 36.1 8 42.1 1.0 Referent —
GC 30 49.2 4 21.1 0.242 0.068–0.869 .038† AC 28 45.9 9 47.4 0.884 0.293–2.666 .827
CC 11 18.0 4 21.1 0.661 0.170–2.577 .740 CC 11 18.0 2 10.5 0.500 0.090–2.765 .696
C carrier 41 67.2 8 42.2 0.355 0.123–1.020 .050 C carrier 39 63.9 11 57.9 0.776 0.271–2.217 .635
Bad prognosis
(relapse or TRD)
GG 14 31.1 17 48.6 1.0 Referent — AA 17 37.8 13 37.1 1.0 Referent —
GC 22 48.9 12 34.3 0.449 0.116–1.218 .113 AC 18 40.0 19 54.3 1.380 0.524–3.634 .514
CC 9 20.0 6 17.1 0.549 0.157–1.920 .345 CC 10 22.2 3 8.6 0.392 0.089–1.721 .307
C carrier 31 68.9 18 51.4 0.478 0.191–1.194 .112 C carrier 28 62.2 22 62.9 1.027 0.412–2.560 .954
TRD: Treatment Resistant Depression; OR: odds ratio; CI: confidence interval.
†Significant p-value.Fisher exact test.
Figure 1. Effect of IL6 genotypes in time to remission in MDD patients. Kaplan–Meier analysis was used to evaluate time to relapse between IL6-174 CC and
GGþGC carriers. Comparison performed by Log-rank test (p¼ .030).
presented significantly lower changes from baseline in IFN-
induced depression (21). This possibility is in accordance
with the evidences from other studies, which have shown
that TRD was associated with a higher level of IL-6 and that
suppression of pro-inflammatory IL-6 cytokine does not
occur in depressed patients who fail to respond to AD, con-
trary to responder patients (6). Additionally, serum IL-6 has
recently been found to be a predictive biomarker for
ketamine’s antidepressant effect in TRD patients (22).
Furthermore, in a GWAS study, an association with response
to escitalopram was observed for the rs7801617 polymorph-
ism of IL6 gene (13).
The effects of IL-6 in antidepressant response are likely to
be explained by its control of SERT levels, and, consequently,
from the serotonin re-uptake. In fact, IL-6 has recently been
recognized to regulate the SERT gene through a STAT3-
dependent regulation region (23). The serotonin transporter
(SERT, SLC6A4) is the main site of action of the most com-
monly prescribed antidepressant drugs (e.g. SSRIs), and SERT
activity is known to affect serotonergic neurotransmission.
Giving this possibility, it is likely that IL6-174G> C genetic
polymorphism, by affecting IL-6 levels/functionality, may
have a consequent impact on SERT, and therefore the sero-
tonin re-uptake (due to the control of SERT by IL-6) might
affect antidepressant response.
Although preliminary, this study demonstrates IL6-174 pro-
moter SNP was associated with TRD development. The rele-
vance of this finding relies on the fact that this SNP has
never been studied in TRD patients and provides a putative
mechanistic link for the dysregulated IL-6 levels described in
the literature in patients with TRD. Functionality studies eval-
uating IL-6 expression in MDD and TRD patients are needed
to fully disclose the role of IL6-174G>C polymorphism.
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